Virosome studied by MedImmune

By Dylan Bushell-Embling
Friday, 18 July, 2008

Technology developed by Norwood Abbey's [ASX: NAL] second-tier subsidiary Virosome Biologicals is being evaluated by US company MedImmune.

The companies have signed a six-month exclusive evaluation agreement over Virosome's virosomal vaccine technology. In this time the companies will collaborate on research using the virosome technology with MedImmune vaccine candidates.

MedImmune is a member of the AstraZeneca group.

Indigenous-led initiative to resurrect the South Island Giant Moa

New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...

Abnormal brain protein targeted in Parkinson's study

Researchers have identified a new brain protein involved in the development of Parkinson's...

Epilepsy disease model treated in a laboratory dish

A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...

Content from other channels on our network

LAPP Australia launches Harnessing Solutions division

Suntory Oceania's $3bn beverage business launched in Qld

Bega Group to close peanut processing business

Konica Minolta and MiR launching two autonomous robots at CeMat

Researchers achieve brine concentration using waste heat or sunlight

Talk from the top with Dr Jayani Chandrapala

Ferrero to acquire WK Kellogg Co for US$3.1bn

AFGC's videos busting myths about processed food

AIP flexible packaging training at Foodtech Packtech

OD200: New Compact Distance Sensor Raising the Bar in Performance and Reliability

A sustainable approach to increase wastewater recycling

City of Gosnells develops tree production nursery

Experts warn against health risks of plastic pollution

Blue Connections IT achieves carbon neutrality through sustainable technology

How real-world events underscore the urgency of climate disclosures